DDInter1628 DDInter3
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Abametapir is a member of bipyridines.
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) upregulates {v} (Gene) KLHL18
KLHL18 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) upregulates {v} (Gene) KLHL18
KLHL18 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) binds {v} (Gene) PHKG2
PHKG2 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) downregulates {v} (Gene) DNAJB2
DNAJB2 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Gastrointestinal haemorrhage
Gastrointestinal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) upregulates KLHL18 (Gene) and KLHL18 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) upregulates KLHL18 (Gene) and KLHL18 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) binds PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) downregulates DNAJB2 (Gene) and DNAJB2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Etoposide (Compound) and PTGS2 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Ruxolitinib (Compound) causes Gastrointestinal haemorrhage (Side Effect) and Gastrointestinal haemorrhage (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir